10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
9.11
-0.34 (-3.60%)
At close: Jun 3, 2025, 4:00 PM
9.09
-0.02 (-0.22%)
After-hours: Jun 3, 2025, 7:27 PM EDT
10x Genomics Stock Forecast
Stock Price Forecast
According to 13 professional analysts, the 12-month price target for 10x Genomics stock ranges from a low of $6.50 to a high of $25. The average analyst price target of $15.81 forecasts a 73.55% increase in the stock price over the next year.
Price Target: $15.81 (+73.55%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 10x Genomics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 7 | 8 | 8 | 8 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 16 | 16 | 16 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $26 → $18 | Buy | Maintains | $26 → $18 | +97.59% | May 19, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $14 | Buy | Reiterates | $14 | +53.68% | May 15, 2025 |
| UBS | UBS | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | +31.72% | May 13, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $7.5 → $6.5 | Strong Sell | Maintains | $7.5 → $6.5 | -28.65% | May 12, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $18 → $15 | Strong Buy | Maintains | $18 → $15 | +64.65% | May 12, 2025 |
Financial Forecast
Revenue This Year
602.17M
from 610.79M
Decreased by -1.41%
Revenue Next Year
642.77M
from 602.17M
Increased by 6.74%
EPS This Year
-1.34
from -1.52
EPS Next Year
-1.04
from -1.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 649.9M | 713.9M | 805.7M | ||
| Avg | 602.2M | 642.8M | 698.1M | ||
| Low | 560.2M | 569.4M | 617.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.4% | 18.6% | 25.3% | ||
| Avg | -1.4% | 6.7% | 8.6% | ||
| Low | -8.3% | -5.4% | -3.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.03 | -0.46 | -0.02 | ||
| Avg | -1.34 | -1.04 | -0.73 | ||
| Low | -1.71 | -1.53 | -1.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.